Is Progression-free Survival Associated with a Better Health-related Quality of Life in Patients with Lung Cancer? Evidence from Two Randomised Trials with Afatinib

Overview

Journal BMJ Open

Specialty General Medicine

Date 2014 Nov 2

PMID 25361836

Citations 8

Authors

Ingolf Griebsch

Michael Palmer

Peter M Fayers

Stuart Ellis

Affiliations

Soon will be listed here.

Abstract

Objective: Progression-free survival (PFS) is frequently used as an efficacy end point in oncology clinical trials. However, there is limited evidence to support a positive association between improvement in PFS and improvement in health-related quality of life (HRQoL). The association between PFS and HRQoL was evaluated in two randomised trials.

Materials And Methods: Data from two randomised controlled trials in patients with non-small cell lung cancer (NSCLC; LUX-Lung 1 and LUX-Lung 3) were used to investigate HRQoL in patients to determine whether tumour progression is accompanied by worsening HRQoL. HRQoL was assessed using the cancer-specific European Organization for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30, the EuroQol EQ-5D overall utility and EuroQol EQ visual analogue scale. In both studies, progression was evaluated by independent review using RECIST criteria (primary end point) and also by investigator assessment. The relationship between tumour progression and HRQoL was evaluated using analysis of covariance and a longitudinal model.

Results: Compliance with HRQoL questionnaire completion was high. In both studies, patients with progression consistently experienced numerically poorer HRQoL at the time of progression than patients without progression. Differences in mean scores were statistically significant (p<0.05) between patients with and without progression at week 4 in all analyses in LUX-Lung 1 and at multiple time points in LUX-Lung 3. Results from the longitudinal analysis showed that progression (by independent review and investigator assessment) appears to have consistent negative impact on all three HRQoL measures (all p<0.0001).

Conclusions: Tumour progression in patients with NSCLC was associated with statistically significant worsening in HRQoL. These findings confirm the value of PFS as a patient-relevant end point.

Citing Articles

Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.

Pilz M, Seyringer S, Al-Naesan I, King M, Bottomley A, Norman R Pharmacoecon Open. 2024; 8(4):627-640.

PMID: 38696019 PMC: 11252099. DOI: 10.1007/s41669-024-00484-9.

Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors.

Gaitonde P, Chirikov V, Kelkar S, Liljas B Cancer Manag Res. 2022; 14:3421-3435.

PMID: 36514307 PMC: 9741849. DOI: 10.2147/CMAR.S380857.

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Goldberg R, Adams R, Buyse M, Eng C, Grothey A, Andre T J Natl Cancer Inst. 2021; 114(6):819-828.

PMID: 34865086 PMC: 9194619. DOI: 10.1093/jnci/djab218.

Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer.

Marschner N, Zacharias S, Lordick F, Hegewisch-Becker S, Martens U, Welt A JAMA Netw Open. 2020; 3(3):e200643.

PMID: 32154886 PMC: 7064873. DOI: 10.1001/jamanetworkopen.2020.0643.

Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.

Jiang S, Walton R, Hueniken K, Baek J, McCartney A, Labbe C Cancer Med. 2019; 8(18):7542-7555.

PMID: 31650705 PMC: 6912023. DOI: 10.1002/cam4.2603.

References

Sherrill B, Amonkar M, Sherif B, Maltzman J, ORourke L, Johnston S . Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010; 15(9):944-53. PMC: 3228031. DOI: 10.1634/theoncologist.2010-0012. View

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

Cella D, Pickard A, Duh M, Guerin A, Mishagina N, Antras L . Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer. 2011; 48(3):311-23. DOI: 10.1016/j.ejca.2011.05.017. View

Miller V, Hirsh V, Cadranel J, Chen Y, Park K, Kim S . Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012; 13(5):528-38. DOI: 10.1016/S1470-2045(12)70087-6. View

Cocks K, King M, Velikova G, de Castro Jr G, Martyn St-James M, Fayers P . Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012; 48(11):1713-21. DOI: 10.1016/j.ejca.2012.02.059. View

. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16(3):199-208. DOI: 10.1016/0168-8510(90)90421-9. View

Soria J, Massard C, Le Chevalier T . Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Ann Oncol. 2010; 21(12):2324-2332. DOI: 10.1093/annonc/mdq204. View

Luo N, Johnson J, Coons S . Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care. 2010; 48(4):365-71. DOI: 10.1097/mlr.0b013e3181c162a2. View

Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16(1):139-44. DOI: 10.1200/JCO.1998.16.1.139. View

10.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

11.

Zhou X, Cella D, Cameron D, Amonkar M, Segreti A, Stein S . Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009; 117(3):577-89. DOI: 10.1007/s10549-009-0310-8. View

12.

Cocks K, King M, Velikova G, Martyn St-James M, Fayers P, Brown J . Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2010; 29(1):89-96. DOI: 10.1200/JCO.2010.28.0107. View

13.

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

14.

Beckman M . More clinical cancer treatments judged by progression-free rather than overall survival. J Natl Cancer Inst. 2007; 99(14):1068-9. DOI: 10.1093/jnci/djm073. View

15.

Yang J, Hirsh V, Schuler M, Yamamoto N, OByrne K, Mok T . Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3342-50. DOI: 10.1200/JCO.2012.46.1764. View

16.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

17.

Villaruz L, Socinski M . The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res. 2013; 19(10):2629-36. PMC: 4844002. DOI: 10.1158/1078-0432.CCR-12-2935. View

18.

Fallowfield L, Fleissig A . The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol. 2011; 9(1):41-7. DOI: 10.1038/nrclinonc.2011.156. View

19.

Bedard G, Zeng L, Lam H, Cella D, Zhang L, Lauzon N . Meaningful change in oncology quality-of-life instruments: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2012; 12(4):475-83. DOI: 10.1586/erp.12.34. View

20.

Pickard A, Neary M, Cella D . Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007; 5:70. PMC: 2248572. DOI: 10.1186/1477-7525-5-70. View